You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Despite promising Phase II data, ipatasertib failed to improve progression-free survival in TNBC patients with PIK3CA, AKT1, or PTEN tumor alterations.
A secondary analysis suggested that using NGS to identify patients with PTEN loss may be better than IHC in identifying best responders to treatment.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.